Premium
Selenium in the treatment of autoimmune thyroiditis
Author(s) -
Gärtner Roland,
Gasnier Barbara C. H.
Publication year - 2003
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.5520190309
Subject(s) - selenium , placebo , medicine , thyroiditis , endocrinology , gastroenterology , autoimmune thyroiditis , chemistry , thyroid , pathology , alternative medicine , organic chemistry
We recently conducted a prospective, placebo‐controlled clinical study, where we could demonstrate, that a substitution of 200 μg sodium selenite for three months in patients with autoimmune thyroiditis reduced thyroid peroxidase antibody (TPO‐Ab) concentrations significantly. Forty‐seven patients from the initially 70 patients agreed to participate in a follow‐up cross‐over study for further six months. One group ( n = 13), which initially received selenium continued to take 200 μg sodium selenite (Se‐Se), one group stopped taking selenium (Se‐0) ( n = 9), another group which received placebo started to take 200 μg selenium ( n = 14) (Plac‐Se) and the last group was without selenium substitution (Plac‐0) ( n = 11). TPO‐Ab concentrations were measured at beginning and the end of the study. In the Se‐Se group, the TPO‐Ab concentrations further significantly p = 0.004) decreased from 625 ± 470 U/ml to 354 ± 321 U/ml, in the Se‐0 group the TPO‐Ab concentrations increased significantly p = 0.017) from 450 ± 335 to 708 ± 313 U/ml. In the placebo group, the TPO‐Ab concentrations in those patients who were followed without selenium substitution were unchanged (1351 ± 940 vs. 1724 ± 1112 U/ml, p = 0.555). In contrast, the patients who received 200 μg sodium selenite after placebo, the TPO‐Ab concentrations decreased significantly ( p = 0.029) from 1182 ± 723 to 643 ± 477 U/ml.